Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kate Sugarman
Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof-Of-Concept, Single-Centre, Open-Label Phase 2a Cohort Study
The Lancet Infectious Diseases
Infectious Diseases
Related publications
Ledipasvir and Sofosbuvir for Recurrent Hepatitis C After Liver Transplantation
BioScience Trends
Biochemistry
Health
Medicine
Genetics
Molecular Biology
NS5A-P32 Deletion After Failure of Ledipasvir/Sofosbuvir in Hepatitis C Virus Genotype 1b Infection
Hepatology
Medicine
Hepatology
Cost Effectiveness Analysis of Sofosbuvir and Ledipasvir/Sofosbuvir in Hepatitis C Virus (HCV) Patients
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
Gastroenterology
Hepatology
Gastroenterology
Ledipasvir / Sofosbuvir for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Across Different Genotype 1 Clinical Subgroups
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Sofosbuvir Plus Ledipasvir for Recurrent Hepatitis C in Liver Transplant Recipients
Liver Transplantation
Hepatology
Transplantation
Surgery
Efficacy and Safety of Ribavirin With Sofosbuvir Plus Ledipasvir in Patients With Genotype 1 Hepatitis C: A Meta-Analysis
Digestive Diseases and Sciences
Physiology
Gastroenterology
Sofosbuvir, Peg Interferon & Ribavirin for Retreatment of HCV Genotype 1b Following Sofosbuvir and Ledipasvir Failure
Hepatology
Medicine
Hepatology
Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in Treatment-Naïve Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis Treated With a Simeprevir/Sofosbuvir/Ledipasvir Regimen
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
